Xenikos aims to develop a new medicine, based on the action of toxin-conjugated antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.

Latest news

11 juni 2019

Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD

20 december 2018

Xenikos partners with the BMT CTN to conduct a U.S.-based Phase 3 trial to test T-Guard® in aGVHD

16 november 2018

Final results from T-Guard® Phase 1/2 trial in steroid-resistant aGVHD published in journal BBMT

To all press releases

Introducing T-Guard®

T-Guard® is a medicine currently under development that safely and swiftly ‘resets’ the body’s immune system. It shows potential in the effective treatment of certain life-threatening immune conditions, such as transplant-related rejection, acute Graft versus Host Disease (aGVHD), solid-organ rejection and several severe autoimmune diseases.

A Patient’s Story

Jan Willem was diagnosed with a rare form of leukemia in 1994. His diagnosis was the start of a remarkable journey to recovery that demonstrates the potential of T-Guard® as a life-saving treatment option.

A Patient’s Story

Jan Willem was diagnosed with a rare form of leukemia in 1994. His diagnosis was the start of a remarkable journey to recovery that demonstrates the potential of T-Guard® as a life-saving treatment option.

Our investors